Rare acquired aplastic anemia

Rare acquired aplastic anemia is a serious hematologic disorder in which the bone marrow fails to produce sufficient blood cells, leading to pancytopenia — a deficiency of red blood cells, white blood cells, and platelets. Unlike inherited forms of aplastic anemia, this condition is acquired during a person's lifetime and is most commonly caused by an autoimmune mechanism in which the body's own T-lymphocytes attack and destroy hematopoietic stem cells in the bone marrow. In many cases, no specific trigger is identified (idiopathic), though recognized triggers can include certain medications (such as chloramphenicol or nonsteroidal anti-inflammatory drugs), chemical exposures (benzene), viral infections (hepatitis viruses, Epstein-Barr virus, parvovirus B19), and radiation exposure. The key clinical features result from the deficiency of each blood cell lineage: anemia causes fatigue, pallor, and shortness of breath; neutropenia (low white blood cells) leads to increased susceptibility to infections; and thrombocytopenia (low platelets) results in easy bruising, petechiae, and an increased risk of bleeding. The severity can range from moderate to very severe, with severe aplastic anemia being a life-threatening condition requiring urgent treatment. The current treatment landscape includes immunosuppressive therapy (IST), typically a combination of anti-thymocyte globulin (ATG) and cyclosporine, which is the standard first-line treatment for patients who are not candidates for transplant. Allogeneic hematopoietic stem cell transplantation (HSCT) from a matched sibling donor is considered the treatment of choice for younger patients with severe disease. The thrombopoietin receptor agonist eltrombopag has been incorporated into first-line IST regimens, showing improved response rates. Supportive care includes blood transfusions, antibiotics, and antifungal prophylaxis. With appropriate treatment, many patients can achieve partial or complete remission, though some may relapse or develop clonal evolution to myelodysplastic syndrome or acute myeloid leukemia over time.

Common questions about Rare acquired aplastic anemia